3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
27
Fallopian Tube Neoplasms
9
Prostatic Neoplasms
8
Breast Neoplasms
8
Neoplasms
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Mesothelioma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Recurrence
2
Mesothelioma, Malignant
2
Melanoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Interventions
Temozolomide
29
Bevacizumab
12
Radiotherapy
10
Irinotecan
7
Carboplatin
7
Carmustine
5
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Cyclophosphamide
4
Cisplatin
4
Vincristine
3
Thiotepa
3
Surgical Procedures, Operative
3
Peripheral Blood Stem Cell Transplantation
3
Etoposide
3
talampanel
2
sargramostim
2
antineoplaston AS 2-1
2
antineoplaston A10
2
abemaciclib
2
Topotecan
2
Thalidomide
2
Tamoxifen
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Procarbazine
2
Immunoglobulin G
2
Everolimus
2
Drug Therapy
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Oligodendroglioma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts